卵巢癌患者血清CEA CA125 HE4 CA724联合检测的临床价值  

The clinical value of detecting the serum levels of CEA,CA125,HE4 and CA724 in patients with ovarian carcinoma

作　　者：于海涛[1] 刘秀娜[1] 

机构地区：[1]威海市文登中心医院,山东威海264400

出　　处：《临床医药实践》2015年第2期100-102,共3页Proceeding of Clinical Medicine

摘　　要：目的:探讨血清CEA,CA125,HE4,CA724联合检测对早期卵巢癌患者诊断的临床价值。方法:选取45例健康体检者、45例卵巢癌患者和45例卵巢良性病变患者,采用酶联免疫法对所有患者血清CEA,CA125,HE4和CA724进行检测。结果:CEA,CA125,HE4和CA724水平卵巢癌患者血清明显比健康患者和卵巢良性病变患者水平高,组间比较差异有统计学意义,P<0.05;健康体检者血清与卵巢良性病变患者比较,差异无统计学意义,P>0.05。结论:血清CEA,CA125,HE4和CA724联合检测对早期卵巢癌患者诊断具有重要意义。Objective： To investigate the clinical value of detecting the serum levels of CEA,CA125,HE4 and CA724 for early diagnosis of ovarian cancer patients. Methods： Serum CEA,CA125,HE4 and CA724 were detected by enzyme- linked immunosorbent assay in subjects,including 45 healthy subjects,45 patients with ovarian cancer and 45 cases of ovarian benign disease patients. Results： Compared with the serum levels of CEA,CA125,HE4 and CA724 in healthy subjects and patients with benign ovarian,that was higher in patients with ovarian cancer. There was significant difference between group,P〈 0. 05.However,no significant difference in serum levels of CEA,CA125,HE4 and CA724 were detected between healthy subjects and patients with ovarian benign lesions,P 〉0.05. Conclusion： The joint detection of CEA,CA125,HE4 and CA724 play an important role in the early diagnosis of patients with ovarian cancer. can increase the detection rate of early ovarian cancer,suitable for clinical use.

关 键 词：联合检测 卵巢癌 酶联免疫法 

分 类 号：R737.31[医药卫生—肿瘤]